Anatomy-based Resection or Margin-based Resection for Hepatocellular Carcinoma

Hepatocellular Carcinoma by BCLC Stage Clinical Trial

Official title: Anatomy-based Resection or Margin-based Resection for Hepatocellular Carcinoma: A Randomized Controlled Trial

Status Not yet recruiting

Clinical Trial Summary

Anatomical liver resection was widely accepted as first line curative therapy for hepatocellular carcinoma. However, number of retrospective clinical studies showed no priority of anatomical resection for hepatocellular, compared with non-anatomical resection.

Surgical resection margin is a essential factor that may affect tumor prognosis. It is controversial whether adequate liver resection margin is associated with improved survival outcome in patients with hepatocellular.

There was few prospective clinical trial to investigate whether anatomical liver resection is superior to non-anatomical resection or liver resection with adequate margin is superior to that with inadequate margin. This prospective clinical trial aims at fix these issues.

Clinical Trial Description

In the anatomical liver resection group, liver segmentectomy or lobectomy is performed to insure curative resection (R0 resection). The region of liver resected is based on the anatomy or portal vein and hepatic vein. The liver pedicle of the tumor located lobe is exposed and dissected, which is principle to perform anatomical liver resection.

In the non-anatomical liver resection group, the liver parenchyma transection is around 0-2 cm from the tumor margin, according to tumor size and location. ;

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma by BCLC Stage

• NCT number: NCT03652896
• Study type: Interventional
• Source: Huazhong University of Science and Technology
• Contact: Binhao Zhang, M.D.
• Phone: +86 83663400
• Email: bhzhang8@163.com
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 1, 2019
• Completion date: December 30, 2023